Furthermore, the combination of AT-II with IFN-γ may induce apoptosis and activate anti-tumor immunity through modulation of the Wnt/β-catenin and NF-κB p65/PD-L1 pathways [57], which likely accounts for the enhanced anti-tumor activity observed with this combination therapy [57]. This evidence concerns the gene CD274 and neoplasm.